摘要
目的应用ROC曲线探讨可溶性Lox-1(sLox-1)、高敏肌钙蛋白I(hs-TnI)单独或联合检测对急性冠脉综合征的诊断价值。方法冠状动脉造影(CAG)确诊的冠心病患者119例(ACS组78例、SA P组41例);NCHD组41例。分别用ELISA,生化免疫分析仪和化学免疫发光仪检测血浆sLox-1、hs-TnI、肌红蛋白、普通肌钙蛋白和CKMB浓度。绘制ROC曲线,用曲线下面积(AUC)等诊断效能参数评价sLox-1和hs-TnI对ACS的诊断价值。结果 sLox-1诊断ACS的AUC为0.934,hs-TnI的AUC为0.918。"sLox-1+hs-TnI"联合检测的AUC为0.974,敏感性为95.1%,特异性为96.2%,高于sLox-1或hs-TnI单独检测及"TnI+Myo+CKMB"联合检测。结论 sLox-1和hs-TnI联合检测可以较好的互补作用,对ACS的诊断具有较高的特异性和敏感性,且高于"TnI+Myo+CKMB"联合检测。
Objective To investigate the diagnostic value of alone or combined detection of Soluble Lox-1 （sLox-1 ） and High-sensitivity Troponin I （hs-TnI） by using ROC curve in acute coronary syndrome （ACS）. Methods 119 patients with ACS had been confirmed by coronary angiography were divided into ACS group （78 patients） and stable angina group （41 patients） , and 41 cases of NCHD patients had also been confirmed by coronary angiography. The serum levels of sLox-1, hs-TnI, Myo, TnI and CKMB in these patients were meas- ured by ELISA, and the Logistic regression model and the area under curve （AUC） of ROC curves were used to evaluate the diagnostic value for ACS. Results The AUC of the ROC curve biomarkers alone and the combination of ＂TnI ＋ Myo ＋ CKMB＂. sLox-1 for sLox-1 and hs-TnI was 0. 934 and 0. 918 respectively. The AUC of the ＂sLox-1 ＋ hs-TnI＂ combination for ACS was 0.974. The diagnostic sensitivity and specificity was 95.1% and 96.2% , respectively, which was higher than that any of the and hs-TnI both have certain value for diagnosing ACS. Conclusion sLox-1 plus hs-TnI combination plays a better role in diagnosing ACS than that either sLox-1 and hs-TnI alone or the ＂TnI ＋ Myo ＋ CKMB＂ combination.
出处
《标记免疫分析与临床》
CAS
2013年第1期1-4,共4页
Labeled Immunoassays and Clinical Medicine
